Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 5, 2016

Primary Completion Date

April 20, 2017

Study Completion Date

September 10, 2019

Conditions

X-Linked Hypophosphatemia

Interventions

BIOLOGICAL

Burosumab

solution for subcutaneous injection

Trial Locations (3)

Indiana University School of Medicine, Indianapolis

Shriners Hospital for Children, St Louis

Yale University School of Medicine, New Haven